Zealand boss considers several new indications for blood sugar remedy

CEO of Zealand Pharma, Emmanuel Dulac, reports that the company is investigating several possible indications for the company's blood sugar drug dasiglucagon, after the firm has started new phase 2 studies with a new indication.

Emmanuel Dulac, CEO of Zealand Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles